Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weifuchun versus teprenone + folic acid for chronic atrophic gastritis
ChiCTR-IPR-17013939Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of weifuchun, teprenone and folic acid in atrophic gastritis (AG) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Total effective rate, Effective rate and 1 more. Started Dec 2017; status: recruiting.
02
Drugs
weifuchunteprenonefolic acid
03
Conditions
atrophic gastritis (AG)
Beyond the preview
Go deeper on ChiCTR-IPR-17013939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013939.